Literature DB >> 25355426

The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis.

Veronica Preda1, Sarah J Larkin, Niki Karavitaki, Olaf Ansorge, Ashley B Grossman.   

Abstract

Craniopharyngiomas are epithelial, sellar tumours with adamantinomatous (aCP) and papillary (pCP) subtypes. The aCP type usually occurs during childhood and pCP in middle-aged adults; aCPs often contain mutations in CTNNB1, encoding β-catenin, a component of the adherens junction and a mediator of Wnt signalling. No such mutational event has been associated with pCPs, where the BRAF gene appears to be more important. In a large series of 95 craniopharyngiomas, we show that the aCP subtype harbours mutations in CTNNB1 in 52 % of cases, while the pCP subtype does not, with agreement between immunohistochemistry and sequencing methods in the majority of cases. When present, the CTNNB1 mutation is found throughout the aCP tumour, while translocation of β-catenin from membrane to cytosol and nucleus is restricted to small cell clusters near the invading tumour front. We observed translocated β-catenin in 100 % of aCPs, occurring not only in cell clusters but also in individual cells scattered throughout the tumour. We characterised the adherens junction involving α-catenin, β-catenin, γ-catenin, p120 and E-cadherin (cytosolic and membranous components). Although suggested to be important in other sellar mass tumourigenesis pathways, there was no disruption of the adherens junction in these tumours, indicating that a loss of junctional integrity is not associated with β-catenin translocation or mutation. We conclude that mutations in CTNNB1 underlie tumourigenesis in the majority of aCPs, which are distinct morphologically and at the molecular level from pCPs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25355426     DOI: 10.1007/s12022-014-9341-8

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  56 in total

1.  Functional interaction of beta-catenin with the transcription factor LEF-1.

Authors:  J Behrens; J P von Kries; M Kühl; L Bruhn; D Wedlich; R Grosschedl; W Birchmeier
Journal:  Nature       Date:  1996-08-15       Impact factor: 49.962

2.  Up-regulation, nuclear import, and tumor growth stimulation of the adhesion protein p120 in pancreatic cancer.

Authors:  Julia Mayerle; Helmut Friess; Markus W Büchler; Jürgen Schnekenburger; Frank U Weiss; Klaus-P Zimmer; Wolfram Domschke; Markus M Lerch
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

3.  The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action.

Authors:  M L Smith; G Hawcroft; M A Hull
Journal:  Eur J Cancer       Date:  2000-03       Impact factor: 9.162

4.  Craniopharyngiomas express embryonic stem cell markers (SOX2, OCT4, KLF4, and SOX9) as pituitary stem cells but do not coexpress RET/GFRA3 receptors.

Authors:  Montserrat Garcia-Lavandeira; Carmen Saez; Esther Diaz-Rodriguez; Sihara Perez-Romero; Ana Senra; Carlos Dieguez; Miguel A Japon; Clara V Alvarez
Journal:  J Clin Endocrinol Metab       Date:  2011-10-26       Impact factor: 5.958

5.  Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.

Authors:  Young A Yoo; Myoung Hee Kang; Hyun Joo Lee; Baek-hui Kim; Jong Kuk Park; Hyun Koo Kim; Jun Suk Kim; Sang Cheul Oh
Journal:  Cancer Res       Date:  2011-10-05       Impact factor: 12.701

6.  Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.

Authors:  Rolf Buslei; Michael Nolde; Bernd Hofmann; Stephan Meissner; Ilker Y Eyupoglu; Florian Siebzehnrübl; Eric Hahnen; Jürgen Kreutzer; Rudolf Fahlbusch
Journal:  Acta Neuropathol       Date:  2005-05-13       Impact factor: 17.088

7.  The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin.

Authors:  A H Huber; W I Weis
Journal:  Cell       Date:  2001-05-04       Impact factor: 41.582

8.  Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.

Authors:  Keisuke Kato; Yukio Nakatani; Hiroshi Kanno; Yoshiyuki Inayama; Rieko Ijiri; Noriyuki Nagahara; Tetsumi Miyake; Mio Tanaka; Yumi Ito; Noriko Aida; Katsuhiko Tachibana; Ken-ichi Sekido; Yukichi Tanaka
Journal:  J Pathol       Date:  2004-07       Impact factor: 7.996

Review 9.  Craniopharyngioma: historical notes.

Authors:  J Lindholm; E H Nielsen
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  SOX2 haploinsufficiency is associated with slow progressing hypothalamo-pituitary tumours.

Authors:  Kyriaki S Alatzoglou; Cynthia L Andoniadou; Daniel Kelberman; Charles R Buchanan; John Crolla; Maria Cristina Arriazu; Martin Roubicek; Daniel Moncet; Juan P Martinez-Barbera; Mehul T Dattani
Journal:  Hum Mutat       Date:  2011-10-11       Impact factor: 4.878

View more
  9 in total

Review 1.  Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.

Authors:  Ruth Prieto; José M Pascual
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

2.  Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.

Authors:  Prit Benny Malgulwar; Aruna Nambirajan; Pankaj Pathak; Mohammed Faruq; Vaishali Suri; Chitra Sarkar; Amandeep Jagdevan; Bhawani Shankar Sharma; Mehar Chand Sharma
Journal:  J Neurooncol       Date:  2017-05-12       Impact factor: 4.130

3.  Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma.

Authors:  Valeria Scagliotti; Laura Avagliano; Angelica Gualtieri; Federica Graziola; Patrizia Doi; Jane Chalker; Andrea Righini; Marta Korbonits; Gaetano Bulfamante; Thomas S Jacques; Valentina Massa; Carles Gaston-Massuet
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

4.  Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?

Authors:  Noriaki Fukuhara; Takeo Iwata; Naoko Inoshita; Katsuhiko Yoshimoto; Masanobu Kitagawa; Hirokazu Fukuhara; Keita Tatsushima; Mitsuo Yamaguchi-Okada; Akira Takeshita; Junko Ito; Yasuhiro Takeuchi; Shozo Yamada; Hiroshi Nishioka
Journal:  Endocr Pathol       Date:  2020-09-23       Impact factor: 3.943

5.  EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke's cleft cysts.

Authors:  Vivian Thimsen; Annett Hölsken; Michael Buchfelder; Jörg Flitsch; Rudolf Fahlbusch; Harald Stefanits; Marco Losa; David T W Jones; Rolf Buslei
Journal:  Sci Rep       Date:  2016-07-19       Impact factor: 4.379

Review 6.  Recent advances in molecular pathology of craniopharyngioma.

Authors:  Sarah Larkin; Niki Karavitaki
Journal:  F1000Res       Date:  2017-07-24

Review 7.  Ten years of research on the role of BVES/ POPDC1 in human disease: a review.

Authors:  Ping Han; Yu Lei; Dongxiao Li; Jingmei Liu; Wei Yan; Dean Tian
Journal:  Onco Targets Ther       Date:  2019-02-18       Impact factor: 4.147

Review 8.  The Embryological Landscape of Mayer-Rokitansky-Kuster-Hauser Syndrome: Genetics and Environmental Factors.

Authors:  Isaac Kyei-Barffour; Miranda Margetts; Alla Vash-Margita; Emanuele Pelosi
Journal:  Yale J Biol Med       Date:  2021-12-29

Review 9.  Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity.

Authors:  Hermann L Müller
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.